ImmunityBio (IBRX)
NASDAQ:IBRX
Top Page
ImmunityBio
(NASDAQ:IBRX)
Select Model
Select Model
Rating:49Neutral
Price Target:
$7.50
▲(5.93% Upside)
Action:ReiteratedDate:04/07/26
The score is held down primarily by weak financial fundamentals (large losses, heavy cash burn, and negative equity). Earnings-call updates provide an offset via strong ANKTIVA commercialization and regulatory progress, while technical signals are mixed with near-term weakness, and valuation remains difficult to support given ongoing losses and no dividend.
Positive Factors
Commercial Revenue Growth
Sustained, rapid scaling of ANKTIVA sales and unit volumes (+750% YoY) demonstrates durable commercial adoption across community and academic channels. Persistent repeat prescribing and sequential quarterly growth indicate an emerging revenue base that can fund continued R&D and expansion of indications over the medium term.
Negative Factors
Heavy Cash Burn & Operating Losses
Persistent, large negative operating and free cash flows far exceed current cash balances, requiring ongoing external funding. Continued heavy cash burn from commercialization and R&D creates structural runway risk absent sustained positive operating cash generation, potentially forcing dilutive or costly financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial Revenue Growth
Sustained, rapid scaling of ANKTIVA sales and unit volumes (+750% YoY) demonstrates durable commercial adoption across community and academic channels. Persistent repeat prescribing and sequential quarterly growth indicate an emerging revenue base that can fund continued R&D and expansion of indications over the medium term.
Read all positive factors
ImmunityBio (IBRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.28B
Dividend YieldN/A
Average Volume (3M)33.48M
Price to Earnings (P/E)―
Beta (1Y)2.06
Revenue Growth1025.95%
EPS Growth52.91%
CountryUS
Employees671
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.06
Shares Outstanding1,028,111,500
10 Day Avg. Volume29,771,178
30 Day Avg. Volume33,479,032
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)-3.65
Price to Sales (P/S)16.08
P/FCF Ratio-5.90
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue69.23
Enterprise Value/Gross Profit74.89
Enterprise Value/Ebitda-35.08
Forecast
1Y Price Target
$13.33Price Target Upside88.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.26
Revenue Forecast (FY)$209.46M
ImmunityBio Business Overview & Revenue Model
Company Description
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunom...
How the Company Makes Money
ImmunityBio makes money primarily by commercializing its approved products and by generating revenue from collaboration-related arrangements where applicable. The company’s key near-term revenue driver is product sales of Anktiva (nogapendekin alf...
ImmunityBio Key Performance Indicators (KPIs)
ImmunityBio Earnings Call Summary
Earnings Call Date:Mar 03, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Positive
The call highlighted strong commercial traction for ANKTIVA with very large year-over-year revenue and unit growth, multiple regulatory milestones (including EU conditional authorization and Saudi first-in-world lung cancer approval), robust enrollment and promising clinical signals across randomized and single-arm QUILT programs, and strategic commercial partnerships and manufacturing initiatives. Offsetting these positives are substantial operating losses and cash burn, significant balance sheet liabilities, continued high R&D investment (including a one-time $14M equipment write-off), and some regulatory delays and market-access complexity in certain cohorts and geographies. Overall, the company is demonstrating clear commercial momentum and clinical progress but remains capital-intensive and faces execution and regulatory risks as it scales internationally.Positive Updates
Transformational Revenue Growth for ANKTIVA
Full-year net product revenue for ANKTIVA was $113.0M in FY2025 versus $14.1M in FY2024, a 700% year-over-year increase; unit sales volume increased ~750% year-over-year, and Q4 revenue of $38.3M represented a 20% sequential increase vs Q3, indicating accelerating commercial adoption.
Negative Updates
Large Net Loss and Cash Burn
Net loss was $351.4M in FY2025; net cash used before operating activities was $304.9M for the year while consolidated cash, cash equivalents and marketable securities stood at $242.8M as of Dec 31, 2025, indicating significant near-term cash burn relative to on‑hand liquidity.
Read all updates
Q4-2025 Updates
Positive
Negative
Transformational Revenue Growth for ANKTIVA
Full-year net product revenue for ANKTIVA was $113.0M in FY2025 versus $14.1M in FY2024, a 700% year-over-year increase; unit sales volume increased ~750% year-over-year, and Q4 revenue of $38.3M represented a 20% sequential increase vs Q3, indicating accelerating commercial adoption.
Read all positive updates
Company Guidance
The company did not provide forward financial guidance on the call but gave extensive 2025 metrics and near‑term milestones: ANKTIVA net product revenue was $113.0M in FY2025 (up 700% vs $14.1M in FY2024) with unit volumes +750% YoY and Q4 revenue $38.3M versus Q3 $31.1M (+20% sequential); ANKTIVA is authorized in 33 countries across four major jurisdictions (US, U.K., EU, KSA) with an EU conditional marketing authorization in Feb‑2026 and two Saudi approvals (bladder and conditional NSCLC combo) in Jan‑2026; cash, cash equivalents and marketable securities were $242.8M at 12/31/2025 and net cash used in operations was $304.9M for the year; FY R&D expense was $218.6M (vs $190.2M in 2024), SG&A was $150M (down from $168.8M), and FY net loss attributable to common stockholders was $351.4M (improved from $413.6M); key liabilities include $505M related‑party convertible notes and ~ $325M revenue‑interest liability. Clinical/regulatory metrics highlighted: QUILT‑2.005 fully enrolled 366 patients (interim 6‑month CR 85% vs 57%; 9‑month 84% vs 52%), QUILT‑3.032 Cohort A CR 71% (n≈100) with duration >53 months and Cohort B 12‑month DFS 58% / 24‑month DFS 52% with 36‑month disease‑specific survival 96% and ~82% bladder preservation; recombinant BCG expanded access spans ~100 sites and ~580 patients with several thousand doses delivered, BCG‑naive enrollment reported at 100% with a targeted BLA in Q4‑2026, QUILT‑3.055 treated ~147 patients, and the company introduced its askIB AI platform and NANT Leonardo automated cell‑manufacturing plans.ImmunityBio Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
18
Very Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 113.29M | 14.74M | 622.00K | 240.00K | 934.00K |
| Gross Profit | 112.53M | 14.74M | 622.00K | 240.00K | 934.00K |
| EBITDA | -223.56M | -264.43M | -478.66M | -351.88M | -320.75M |
| Net Income | -351.40M | -413.56M | -583.20M | -416.57M | -346.79M |
Balance Sheet | |||||
| Total Assets | 501.90M | 382.93M | 504.45M | 362.36M | 468.91M |
| Cash, Cash Equivalents and Short-Term Investments | 242.82M | 149.81M | 266.46M | 107.18M | 317.12M |
| Total Debt | 878.12M | 504.17M | 726.72M | 723.77M | 645.66M |
| Total Liabilities | 1.00B | 871.06M | 1.09B | 812.18M | 712.82M |
| Stockholders Equity | -499.57M | -489.10M | -586.99M | -447.33M | -242.17M |
Cash Flow | |||||
| Free Cash Flow | -308.78M | -398.12M | -397.34M | -415.67M | -307.98M |
| Operating Cash Flow | -304.94M | -391.24M | -366.76M | -337.51M | -274.42M |
| Investing Cash Flow | -149.80M | -12.25M | -30.47M | 27.30M | -84.89M |
| Financing Cash Flow | 400.24M | 281.63M | 558.34M | 233.61M | 505.44M |
ImmunityBio Technical Analysis
Negative
7.08
Price Trends
7.75
Negative
5.16
Positive
3.86
Positive
Market Momentum
-0.21
Positive
44.82
Neutral
22.01
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IBRX, the sentiment is Negative. The current price of 7.08 is below the 20-day moving average (MA) of 7.94, below the 50-day MA of 7.75, and above the 200-day MA of 3.86, indicating a neutral trend. The MACD of -0.21 indicates Positive momentum. The RSI at 44.82 is Neutral, neither overbought nor oversold. The STOCH value of 22.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IBRX.
ImmunityBio Risk Analysis
ImmunityBio disclosed 95 risk factors in its most recent earnings report. ImmunityBio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ImmunityBio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
84 Outperform | $3.05B | 13.32 | 24.32% | ― | 25.56% | 44.42% | |
63 Neutral | $2.93B | -228.91 | -10.26% | ― | 129.21% | 80.35% | |
62 Neutral | $5.07B | -10.43 | -65.80% | ― | ― | -27.70% | |
54 Neutral | $2.47B | -34.27 | -7.31% | ― | -84.07% | -157.71% | |
53 Neutral | $1.62B | -19.61 | -6.93% | ― | 27.51% | 38.72% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $7.28B | -5.18 | 64.30% | ― | 1025.95% | 52.91% |
* Healthcare Sector Average
IBRX
ImmunityBio
6.86
4.44
183.47%
CPRX
Catalyst Pharma
24.99
3.59
16.78%
IMVT
Immunovant
24.61
11.30
84.90%
ARQT
Arcutis Biotherapeutics
23.27
9.98
75.09%
BEAM
Beam Therapeutics
24.49
9.95
68.43%
IMCR
Immunocore Holdings
31.96
7.43
30.29%
ImmunityBio Corporate Events
Business Operations and StrategyLegal ProceedingsRegulatory Filings and Compliance
ImmunityBio Addresses FDA Warning on ANKTIVA Promotion
Negative
Apr 6, 2026
On April 6, 2026, ImmunityBio, Inc. announced it had submitted a comprehensive response to a March 13, 2026 Warning Letter from the U.S. FDA’s Office of Prescription Drug Promotion concerning a podcast and a television advertisement related ...
Business Operations and StrategyPrivate Placements and Financing
ImmunityBio Bolsters Balance Sheet With New Financing Moves
Positive
Mar 31, 2026
On March 30, 2026, ImmunityBio amended its Revenue Interest Purchase Agreement with Oberland Capital, securing an additional $75 million in non-dilutive financing that lifts total committed capital under the structure to $375 million. In exchange,...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
ImmunityBio Wins EU Nod for ANKTIVA Bladder Cancer Therapy
Positive
Feb 18, 2026
On February 18, 2026, ImmunityBio announced that the European Commission granted conditional marketing authorization for ANKTIVA in combination with BCG to treat adult patients with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in ...
Business Operations and StrategyPrivate Placements and Financing
ImmunityBio Amends Major Insider Convertible Note Agreement
Positive
Jan 26, 2026
On January 23, 2026, ImmunityBio, Inc. amended a $505 million Second Amended and Restated Convertible Promissory Note originally dated December 10, 2024, with Nant Capital, LLC, an affiliate of Executive Chairman and Global Chief Scientific and Me...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
ImmunityBio Wins Saudi Approvals for ANKTIVA Cancer Therapies
Positive
Jan 14, 2026
On January 14, 2026, ImmunityBio announced that the Saudi Food and Drug Authority granted accelerated approval of ANKTIVA® (nogapendekin alfa inbakicept) in combination with immune checkpoint inhibitors for adult patients with metastatic non-...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.